Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Recbio Plans to Raise $98 Million in a Hong Kong IPO for Vaccines

publication date: Mar 21, 2022

Jiangsu Recbio Technology (HK: 2179) is conducting a $98 million Hong Kong IPO to support development of its vaccine portfolio. Recbio has a portfolio of 12 vaccine candidates including its lead product, a recombinant HPV 9-valent vaccine currently being tested in a Phase III clinical trial. The company is focused on protein-based subunit vaccines that present an antigen to the immune system without viral particles. Last year, Recbio formed a JV with Shenzhen Rhegen Biotech to develop an mRNA vaccine for COVID-19. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022